
Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer. Incidence of liver cancer varies geographically and parallels with the geographic prevalence of viral hepatitis. A number of staging systems have been developed, reflecting the heterogeneity of primary liver cancer, regional preferences, and regional variations in resectability or transplant eligibility. Multimodality treatments are available for this heterogeneous malignancy, and there are variations in the management recommendations for liver cancers across specialties and geographic regions. Novel treatment strategies have merged with the advance of new treatment modalities. This work focuses on reviewing the incidence, staging, and treatment of liver cancer.
Oncolytic Virotherapy, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, Combined Modality Therapy, Liver Transplantation, Catheter Ablation, Hepatectomy, Humans, Immunotherapy, Molecular Targeted Therapy, Neoplasm Staging
Oncolytic Virotherapy, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, Combined Modality Therapy, Liver Transplantation, Catheter Ablation, Hepatectomy, Humans, Immunotherapy, Molecular Targeted Therapy, Neoplasm Staging
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 351 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 0.1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
